Home > Result Summaries: Compounds > ropinirole > Result Summary for 112771

Result Summary for 112771

Result Summary

Protocol ID:	112771
Clinical Study ID:	ROP112771
Official Title:	An open label study conducted in healthy subjects to demonstrate bioequivalence between ropinirole prolonged release tablets (ropinirole XL, marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) manufactured at Crawley and Aranda
Phase:	phase 1
Study Indications or Diseases:	Parkinson Disease
Generic Name:	Ropinirole
Trade/Product Name:	Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	GSK has concluded that it is not feasible to publish this study in a peer-reviewed scientific journal because the nature of the study is unlikely to be of interest to a journal. GSK is providing the attached study results summary.